PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR

摘要

#$%^&*AU2013228033A120131003.pdf#####ABSTRACT A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. 5